Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a
significant threat to public health, because it can lead to impaired liver function and liver
failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate
metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than
individuals without obesity. There are data to suggest that growth hormone may help to reduce
the amount of fat in the liver, and may also reduce inflammation in the liver, both of which
would be helpful to individuals with NAFLD. The purpose of this study is to investigate
whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone
analogue, will decrease liver fat and improve liver inflammation and scarring in obese
individuals with NAFLD.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.